NEW YORK – The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized Novartis' Kisqali (ribociclib) in combination with an aromatase inhibitor as a treatment for patients with ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association between aromatase inhibitor treatment (AIT) and ischaemic cardiotoxicity ...

Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

However, given the recent failure of Sanofi's oral SERD amcenestrant in the phase 2 AMEERA-3 trial – which included a similar patient population – the new result is a worrying readout for the ...

Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China ...

The decision to abandon development of the oral selective oestrogen receptor degrader (SERD) comes after an ... patients who have discontinues aromatase inhibitor therapy due to toxicity.

In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade. However, expanded ...

Sex hormones have been implicated in neurite outgrowth, synaptogenesis, dendritic branching, myelination and other important mechanisms of neural plasticity. Here we review the evidence from animal ...

SRC1 was the first cloned steroid receptor co-activator that interacts with steroid hormone receptors to promote transcriptional activation in a hormone-dependent manner. The p160 SRC family ...